106 related articles for article (PubMed ID: 7747997)
21. Endocrine management of breast cancer.
Schneider PG; Jackisch C; Brandt B
Int J Fertil Menopausal Stud; 1994; 39 Suppl 2():115-27. PubMed ID: 7874188
[TBL] [Abstract][Full Text] [Related]
22. Preventing relapse beyond 5 years: the MA.17 extended adjuvant trial.
Goss PE
Semin Oncol; 2006 Apr; 33(2 Suppl 7):S8-12. PubMed ID: 16730271
[TBL] [Abstract][Full Text] [Related]
23. Extended adjuvant endocrine therapy of early breast cancer.
Chowdhury S; Ellis P
Curr Med Res Opin; 2005 Dec; 21(12):1985-95. PubMed ID: 16368050
[TBL] [Abstract][Full Text] [Related]
24. Endocrine therapy for early breast cancer.
Hussain SA; Williams S; Stevens A; Rea DW
Expert Rev Anticancer Ther; 2004 Oct; 4(5):877-88. PubMed ID: 15485321
[TBL] [Abstract][Full Text] [Related]
25. The use of early adjuvant aromatase inhibitor therapy: contributions from the BIG 1-98 letrozole trial.
Forbes JF
Semin Oncol; 2006 Apr; 33(2 Suppl 7):S2-7. PubMed ID: 16730270
[TBL] [Abstract][Full Text] [Related]
26. The use of third-generation aromatase inhibitors and tamoxifen in the adjuvant treatment of postmenopausal patients with hormone-dependent breast cancer: evidence based review.
Poole R; Paridaens R
Curr Opin Oncol; 2007 Nov; 19(6):564-72. PubMed ID: 17906453
[TBL] [Abstract][Full Text] [Related]
27. Postoperative adjuvant chemotherapy followed by adjuvant tamoxifen versus nil for patients with operable breast cancer: a randomised phase III trial of the European Organisation for Research and Treatment of Cancer Breast Group.
Morales L; Canney P; Dyczka J; Rutgers E; Coleman R; Cufer T; Welnicka-Jaskiewicz M; Nortier J; Bogaerts J; Therasse P; Paridaens R; ;
Eur J Cancer; 2007 Jan; 43(2):331-40. PubMed ID: 17134892
[TBL] [Abstract][Full Text] [Related]
28. Co-expression of estrogen receptor alpha and Apolipoprotein D in node positive operable breast cancer--possible relevance for survival and effects of adjuvant tamoxifen in postmenopausal patients.
Søiland H; Skaland I; Varhaug JE; Kørner H; Janssen EA; Gudlaugsson E; Baak JP; Søreide JA
Acta Oncol; 2009; 48(4):514-21. PubMed ID: 19107621
[TBL] [Abstract][Full Text] [Related]
29. Current and future status of adjuvant therapy for breast cancer.
Coleman RE
Cancer; 2003 Feb; 97(3 Suppl):880-6. PubMed ID: 12548590
[TBL] [Abstract][Full Text] [Related]
30. [A randomized controlled study comparing uracil-tegafur (UFT)+tamoxifen (UFT+TAM therapy) with cyclophosphamide+adriamycin+5-fluorouracil (CAF therapy) for women with stage I , II, or IIIa breast cancer with four or more involved nodes in the adjuvant setting].
Inaji H; Sakai K; Oka T; Ozawa K; Saito Y; Senoo T; Taguchi T; Terasawa T; Nakao K; Mori T; Koyama H; Oshima A
Gan To Kagaku Ryoho; 2006 Oct; 33(10):1423-9. PubMed ID: 17033231
[TBL] [Abstract][Full Text] [Related]
31. Luteinising hormone releasing hormone agonists (LH-RHa) in premenopausal early breast cancer patients: current role and future perspectives.
Del Mastro L; Levaggi A; Giraudi S; Pronzato P
Cancer Treat Rev; 2011 May; 37(3):208-11. PubMed ID: 20724078
[TBL] [Abstract][Full Text] [Related]
32. [Clinical benefit of antiestrogens for breast cancer].
Iino Y; Koibuchi Y
Nihon Rinsho; 2008 Jan; 66(1):168-73. PubMed ID: 18193554
[TBL] [Abstract][Full Text] [Related]
33. Role of tamoxifen in the long-term treatment and prevention of breast cancer.
Jordan VC
Oncology (Williston Park); 1988 Sep; 2(9):19-28. PubMed ID: 3079292
[TBL] [Abstract][Full Text] [Related]
34. Potential use of analogs of luteinizing hormone-releasing hormones in the treatment of hormone-sensitive neoplasms.
Schally AV; Redding TW; Comaru-Schally AM
Cancer Treat Rep; 1984 Jan; 68(1):281-9. PubMed ID: 6362868
[TBL] [Abstract][Full Text] [Related]
35. Adjuvant therapy with GnRH agonists/tamoxifen in breast cancer should be a good council for patients with hormone receptor-positive tumours and wish to preserve fertility.
Franco JG; Oliveira JB; Petersen CG; Mauri AL; Baruffi R; Cavagna M
Med Hypotheses; 2012 Apr; 78(4):442-5. PubMed ID: 22284634
[TBL] [Abstract][Full Text] [Related]
36. Role of adjuvant endocrine therapy in early-stage breast cancer.
Muss HB
Semin Oncol; 2001 Aug; 28(4):313-21. PubMed ID: 11498825
[TBL] [Abstract][Full Text] [Related]
37. [Experimental multihormone therapy on human breast carcinomas grown in nude mice].
Fukutomi T
Nihon Geka Gakkai Zasshi; 1989 Dec; 90(12):2021-30. PubMed ID: 2626154
[TBL] [Abstract][Full Text] [Related]
38. [Postoperative adjuvant therapy for premenopausal patients with breast cancer].
Kurebayashi J
Nihon Rinsho; 2006 Oct; 64(10):1963-9. PubMed ID: 17037375
[TBL] [Abstract][Full Text] [Related]
39. Toremifene, rather than tamoxifen, might be a better option for the adjuvant endocrine therapy in CYP2D6*10T/T genotype breast cancer patients in China.
Lan B; Ma F; Chen S; Wang W; Li Q; Fan Y; Luo Y; Cai R; Wang J; Yuan P; Zhang P; Li Q; Xu B
Int J Cancer; 2018 Nov; 143(10):2499-2504. PubMed ID: 29978573
[TBL] [Abstract][Full Text] [Related]
40. [Treatment strategy for recurrent breast cancer].
Takatsuka Y; Shin E
Gan To Kagaku Ryoho; 1998 Feb; 25(3):309-13. PubMed ID: 9492821
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
